Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years at the time of consent. * Pathologically or cytologically confirmed eligible disease: B-ALL; B-cell NHL/CLL/SLL; multiple myeloma/plasma cell leukemia; AML/high-risk MDS/BPDCN; or T-ALL/T-LBL/peripheral T-cell lymphoma. * Relapsed or refractory disease after at least 2 prior lines of therapy, or no curative/approved standard option judged appropriate by the investigator. * Central laboratory confirmation that at least one active dual-target module is suitable based on malignant-cell antigen co-expression and safety review. * Measurable or otherwise evaluable disease by disease-specific response criteria. * ECOG performance status 0 to 2. * Adequate organ function: LVEF \>= 45%; creatinine clearance \>= 40 mL/min; AST/ALT \<= 3 x ULN; total bilirubin \<= 1.5 x ULN unless due to Gilbert syndrome; oxygen saturation \>= 92% on room air. * Adequate hematologic reserve unless cytopenia is clearly disease-related. * Ability to undergo leukapheresis and willingness to comply with study procedures and follow-up. * If prior allogeneic HSCT: at least 100 days from transplant, no uncontrolled GVHD, and no systemic immunosuppression above physiologic steroid replacement. * Negative pregnancy test for participants of childbearing potential and agreement to use effective contraception during protocol-defined risk periods. * Written informed consent obtained before any study-specific procedure. Exclusion Criteria: * \- Active uncontrolled infection, including uncontrolled bacterial, fungal, or viral infection, or clinical sepsis. * Active symptomatic CNS involvement requiring escalating therapy; previously treated/stable CNS disease may be allowed if defined prospectively in the final protocol. * Prior gene-modified cellular therapy within 12 weeks before leukapheresis, or unresolved \>= Grade 3 toxicity from prior anticancer therapy * Need for urgent cytoreduction such that manufacturing delay would create unacceptable clinical risk. * Active autoimmune disease requiring systemic immunosuppression, except limited replacement-dose steroids or protocol-permitted topical/inhaled therapy. * Prior solid organ transplant. * Clinically significant cardiovascular disease, uncontrolled arrhythmia, decompensated heart failure, myocardial infarction within 6 months, or recent stroke within 6 months. * Uncontrolled HIV, HBV, or HCV viremia. * Pregnancy or breastfeeding. * Another active malignancy requiring systemic therapy, unless low-risk and definitively treated per protocol-defined exceptions. * Known hypersensitivity to fludarabine, cyclophosphamide, or critical product excipients. * Inability to manufacture a releaseable CAR-T product or failure to meet module-specific product-release criteria. * Any medical, psychiatric, or social condition that, in the investigator's judgment, would increase risk, impair compliance, or confound interpretation of study results.